Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B, Bolaños E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sánchez-Paulete AR, Chen L, Friedl P, Melero I. Weigelin B, et al. Among authors: wagena e. Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1. Proc Natl Acad Sci U S A. 2015. PMID: 26034288 Free PMC article.
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells.
Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, de Jonge PKJD, Evert JSH, van der Waart AB, Cany J, Safrit JT, Lee JH, Wagena E, Friedl P, Önfelt B, Massuger LF, Schaap NPM, Jansen JH, Hobo W, Dolstra H. Van der Meer JMR, et al. Among authors: wagena e. Cancer Immunol Immunother. 2021 May;70(5):1305-1321. doi: 10.1007/s00262-020-02749-8. Epub 2020 Nov 3. Cancer Immunol Immunother. 2021. PMID: 33140189 Free PMC article.
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.
Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, De Jonge PKJD, Hoogstad-van Evert JS, van der Waart AB, Cany J, Safrit JT, Lee JH, Wagena E, Friedl P, Önfelt B, Massuger LF, Schaap NPM, Jansen JH, Hobo W, Dolstra H. Van der Meer JMR, et al. Among authors: wagena e. Cancer Immunol Immunother. 2021 Nov;70(11):3367. doi: 10.1007/s00262-021-03049-5. Cancer Immunol Immunother. 2021. PMID: 34524494 Free PMC article. No abstract available.
Part 1: Defining unproven cellular therapies.
Srivastava A, Mason C, Wagena E, Cuende N, Weiss DJ, Horwitz EM, Dominici M. Srivastava A, et al. Among authors: wagena e. Cytotherapy. 2016 Jan;18(1):117-9. doi: 10.1016/j.jcyt.2015.11.004. Cytotherapy. 2016. PMID: 26719202 Free article. No abstract available.
Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective.
Dominici M, Nichols K, Srivastava A, Weiss DJ, Eldridge P, Cuende N, Deans RJ, Rasko JE, Levine AD, Turner L, Griffin DL, O'Donnell L, Forte M, Mason C, Wagena E, Janssen W, Nordon R, Wall D, Ho HN, Ruiz MA, Wilton S, Horwitz EM, Gunter KC; 2013–2015 ISCT Presidential Task Force on Unproven Cellular Therapy. Dominici M, et al. Among authors: wagena e. Cytotherapy. 2015 Dec;17(12):1663-6. doi: 10.1016/j.jcyt.2015.10.007. Cytotherapy. 2015. PMID: 26589750 No abstract available.
38 results